IDEX Corporation (NYSE: IEX) recently announced its financial results for the three-month period ended June 30, 2025. The company reported record sales of $865 million, representing a 7% increase from the prior year period. When considering organic growth, sales increased by 1%.
The reported diluted EPS of $1.74 declined by 6%, while the adjusted diluted EPS of $2.07 remained relatively flat year-over-year, surpassing second quarter expectations.
Orders for the period totaled $829.8 million, reflecting a 7% increase from the prior year period. However, organic orders increased by 2%, which is below the year-to-date average.
IDEX Corporation is revising its full-year EPS outlook to GAAP diluted EPS of $6.30 * $6.44 and adjusted diluted EPS of $7.85 * $7.95, indicating a change from the previous guidance of $6.56 * $6.95 (adjusted diluted EPS of $8.10 * $8.45).
The company expressed confidence in its sustainable value creation engine built through integrated growth strategies and balanced capital deployment strategies. CEO and President, Eric D. Ashleman, highlighted the strong execution of IDEX teams in a challenging operating environment during the second quarter.
Looking ahead, the company expects to generate GAAP diluted EPS of $1.54 * $1.61 (adjusted diluted EPS of $1.90 * $1.95) in the third quarter of 2025, based on expected organic sales growth of 2% to 3%.
In terms of consolidated financial results for the three months ended June 30, 2025, ID orders increased by 7% to $829.8 million, while net sales saw a 7% increase to $865.4 million.
The company reported a net income attributable to IDEX of $131.6 million, reflecting a decrease of 9.7% from the prior year period. Diluted EPS attributable to IDEX was $1.74, a decrease of $0.12.
Cash flows from operating activities increased to $161.7 million, representing a 28.1% increase from the prior year period, with operating cash flow as a percentage of net income reaching 123%.
When examining non-GAAP results, organic orders increased by 2%, and organic sales increased by 1%. Adjusted gross profit remained relatively flat at $392.2 million, while adjusted net income attributable to IDEX was $156.5 million, a marginal increase from the prior year period.
Segment-wise, the Health & Science Technologies segment's net sales increased by 20%, driven by the acquisition of Mott. The Fluid & Metering Technologies segment saw a decrease of 3% in net sales, while the Fire & Safety/Diversified Products segment experienced a 3% increase in net sales.
Following these announcements, the company's shares moved -9.7%, and are now trading at a price of $167.21. Check out the company's full 8-K submission here.
